Biosimilars – Pharma.Tips

Biosimilars in Pharma: Development, Regulatory Approval, and GMP Practices

A biosimilar is a biologic product that shows no clinically meaningful differences from an existing approved reference product. Unlike generics, which are identical chemical copies, biosimilars are not exact duplicates…

Comprehensive Guide to Biosimilars: Development, Regulations, and Market Access

Biosimilars are biotherapeutic products that are highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, and potency. Unlike generics, biosimilars are not exact…

Biosimilar Comparability Gaps? Analytical and Regulatory Pathway Solutions

In the pharmaceutical landscape, particularly when dealing with biosimilars, it is critical to recognize early signals indicating comparability gaps. These symptoms may appear in various forms:Click to read the full…

Biosimilar aggregate level increase after cell line or upstream change: CAPA strategy to restore similarity and prevent regulatory delays

Recognizing symptoms that indicate a rise in aggregate levels is critical to the timely identification of underlying issues. Some potential signals to look out for include:Click to read the full…

Biosimilar comparability package deficiency during biosimilar development: risk assessment for critical quality attributes and clinical impact

Detecting symptoms of a biosimilar comparability package deficiency begins in the lab or during production. These symptoms can manifest as:Click to read the full article.

Biosimilar method transfer failure across labs during stability pull comparisons: FDA/EMA expectations for root cause, rework, and comparability justification

Recognizing early signals of method transfer failure is critical. Symptoms may emerge through various channels, recommending immediate attention to the process. Here are typical indicators observed on the manufacturing floor…

Biosimilar process change without bridging study during commercial launch readiness: decision tree for lab method variability vs true product differences

Recognizing signals on the production floor or in the lab can provide early warnings of potential issues with biosimilars. These symptoms often manifest as unexpected variability in analytical results, inconsistent…

Biosimilar charge variant profile drift during CPV trending review: risk assessment for critical quality attributes and clinical impact

Timely recognition of symptoms related to charge variant profile drift is paramount. Key signals may include:Click to read the full article.

Biosimilar potency OOS vs reference product during comparability protocol execution: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying signals indicating potential issues with biosimilar potency is crucial for timely intervention. Symptoms of OOS during comparability testing may include:Click to read the full article.

Biosimilar method transfer failure across labs during FDA/EMA scientific advice / meetings: bridging study planning and regulatory communication strategy

Identifying symptoms or signals indicative of a biosimilar method transfer failure requires vigilant monitoring across multiple facets of the laboratory and manufacturing environment. Symptoms may manifest as:Click to read the…

Biosimilar reference standard qualification gap during biosimilar development: risk assessment for critical quality attributes and clinical impact

Identifying signals that indicate potential qualification gaps in the biosimilar development process is essential. Symptoms may manifest in various ways:Click to read the full article.

Biosimilar functional assay variability (cell-based assay) during commercial launch readiness: FDA/EMA expectations for root cause, rework, and comparability justification

Recognizing signs of assay variability is the first critical step in managing quality control within biosimilar manufacturing. Some common symptoms that may indicate functional assay variability include:Click to read the…